Security
PDS Biotechnology Corporation Common Stock · PDSB
PDSBNASDAQCommon stockCurrentCIK 1472091Updated Nov 13, 2026
Name history
Edge Therapeutics, Inc. · through Mar 18, 2019
PDSB price & chart
Loading TradingView…
NASDAQ:PDSB on TradingView ↗About the company
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
In the news
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 News provided by Equity Insider Aug 14, 2025, 12:30 ET Share this article Share to X Share this article Share to X Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNewswire/ -- E ↗
Seeking Alpha
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow ↗
PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript ↗
PDS Biotech outlines VERSATILE-003 amendment targeting interim PFS with approximately 250 patients ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
4 filing
3 filing
Show 5 more recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01, 9.01
S-3 filing
Other Events
Items 8.01, 9.01
Other Events
Items 8.01, 9.01
SCHEDULE 13D - filed by Nant Capital, LLC regarding PDS Biotechnology Corp
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 34,705,801Source | 52,450,653Source | 8,807,213Source | 40,476,065Source | 60,495,947Source | 24,663,026Source | 47,028,542Source | 69,006,366Source | 30,494,083Source | 45,358,657Source | 59,390,080Source | 77,007,923Source |
| Property, Plant and Equipment, NetUSD | 125,643Source | 147,479Source | 176,612Source | 131,102Source | 152,938Source | 114,725Source | 136,561Source | 129,398Source | 120,184Source | 142,020Source | 134,132Source | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 26,198,652Source | 49,751,252Source | 5,596,254Source | 31,873,495Source | 57,733,724Source | 21,660,496Source | 39,978,674Source | 66,634,417Source | 26,711,969Source | 41,689,591Source | 56,560,517Source | 73,820,160Source |
| Assets, CurrentUSD | 27,892,910Source | 52,131,311Source | 7,045,193Source | 33,648,045Source | 60,161,476Source | 22,885,877Source | 42,468,639Source | 68,685,765Source | 28,254,085Source | 45,054,443Source | 59,055,075Source | 76,480,390Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,694,258Source | 2,380,059Source | 1,448,939Source | 1,774,550Source | 2,427,752Source | 1,225,381Source | 2,489,965Source | 2,051,348Source | 1,542,116Source | 3,364,852Source | 2,494,558Source | 2,660,230Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 152,645Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 25,252,291Source | 30,449,848Source | 12,386,952Source | 24,516,281Source | 29,578,077Source | 20,770,383Source | 24,666,333Source | 31,823,321Source | 21,242,250Source | 26,353,809Source | 33,259,133Source | 33,005,893Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 15,744Source | 12,150Source | 18,455Source | 15,390Source | 12,137Source | 18,420Source | 14,998Source | 12,104Source | 18,111Source | 12,536Source | 10,921Source | 9,956Source |
| Additional Paid in CapitalUSD | 218,481,351Source | 196,147,302Source | 230,107,941Source | 215,978,568Source | 194,337,722Source | 227,829,783Source | 212,947,177Source | 192,275,033Source | 225,840,226Source | 201,103,311Source | 170,620,641Source | 145,550,491Source |
| Retained Earnings (Accumulated Deficit)USD | -209,043,585Source | -174,158,647Source | -233,706,135Source | -200,034,174Source | -163,431,989Source | -223,955,560Source | -190,599,966Source | -155,104,092Source | -216,606,504Source | -182,110,999Source | -144,500,615Source | -101,558,417Source |
| Stockholders' Equity Attributable to ParentUSD | 9,453,510Source | 22,000,805Source | -3,579,739Source | 15,959,784Source | 30,917,870Source | 3,892,643Source | 22,362,209Source | 37,183,045Source | 9,251,833Source | 19,004,848Source | 26,130,947Source | 44,002,030Source |
| Liabilities and EquityUSD | 34,705,801Source | 52,450,653Source | 8,807,213Source | 40,476,065Source | 60,495,947Source | 24,663,026Source | 47,028,542Source | 69,006,366Source | 30,494,083Source | 45,358,657Source | 59,390,080Source | 77,007,923Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,329,460Source | 18,340,203Source | 12,377,476Source | 11,531,452Source | 15,674,774Source | 10,146,725Source | 18,265,345Source | 15,063,690Source | 9,483,214Source | 17,087,201Source | 13,629,977Source | 9,821,036Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 231,429Source |
| Accounts Payable, CurrentUSD | 5,180,928Source | 1,300,920Source | 6,393,967Source | 4,497,434Source | 3,252,490Source | 3,650,352Source | 2,859,292Source | 6,000,831Source | 3,574,448Source | 1,684,868Source | 6,982,824Source | 1,219,287Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,104,390Source | 4,479,541Source | 1,629,313Source | 1,482,081Source | 1,947,221Source | 1,258,817Source | 2,846,497Source | 1,714,111Source | 742,227Source | 2,841,214Source | 2,424,692Source | 8,313,708Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,156,495Source | 1,253,882Source | 4,106,606Source | 6,848,193Source | 7,614,321Source | 5,196,156Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 75,904Source | 1,174,424Source | 1,889,580Source | -5,297,956Source | 5,763,537Source | -90,116Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,371,646Source | -9,032,256Source | -27,752,012Source | -35,030,223Source | -33,636,136Source | -25,709,706Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | -29,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 0Source | 29,000Source | — | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 270,959Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -679,827Source | 7,321,339Source | 12,774,390Source | 20,188,297Source | 16,376,493Source | 34,287,244Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 26,198,652Source | 49,751,252Source | 5,596,254Source | 31,873,495Source | 21,660,496Source | 39,978,674Source | 26,711,969Source | 41,689,591Source | 56,560,517Source | 73,820,160Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 564,653Source | 693,989Source | 2,921,359Source | 3,556,662Source | 3,535,071Source | 852,221Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | -1,162,953Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,246,485Source | 1,778,272Source | 1,126,054Source | 448,029Source | 1,156,495Source | 1,253,882Source | 4,106,606Source | 6,848,193Source | 7,614,321Source | 5,196,156Source |
| DepreciationUSD | — | — | — | — | — | — | 5,459Source | 5,459Source | 21,836Source | 21,112Source | 17,359Source | 86Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | -1,107,004Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,563,753Source | 3,374,794Source | 3,231,148Source | 3,410,433Source | 3,064,055Source | 3,274,759Source | 12,518,127Source | 13,755,671Source | 15,282,450Source | 12,241,394Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | -1,169,820Source | -1,169,820Source | -869,169Source | -1,406,019Source | -1,198,905Source |
| InterestExpenseNonoperatingUSD | — | — | 1,150,378Source | 1,214,734Source | 3,379,246Source | 2,144,481Source | 1,014,783Source | 930,878Source | 5,338,607Source | 4,673,174Source | — | — |
| Investment Income, InterestUSD | — | — | 281,109Source | 666,770Source | 125,405Source | 333,624Source | 186,814Source | 377,849Source | 1,217,241Source | 2,514,816Source | 2,902,939Source | 935,180Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -9,009,411Source | -10,726,658Source | -9,750,575Source | -9,434,208Source | -7,349,056Source | -8,488,967Source | -34,495,505Source | -37,610,384Source | -42,942,198Source | -40,854,855Source |
| Operating ExpensesUSD | — | — | 8,140,142Source | 10,178,694Source | 6,496,734Source | 7,623,351Source | 6,521,087Source | 9,105,758Source | 31,543,959Source | 36,321,195Source | 43,045,234Source | 41,672,421Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 241,029Source |
| Pension Expense (Reversal of Expense), NoncashUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 0Source | 6,994,174Source | 9,709,064Source | 22,595,001Source | 16,126,851Source | 9,856,116Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 0Source | 774,091Source | 308,942Source | 151,416Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -8,140,142Source | -10,178,694Source | -6,496,734Source | -7,623,351Source | -6,521,087Source | -9,105,758Source | -31,543,959Source | -36,321,195Source | -43,045,234Source | -41,672,421Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -9,009,411Source | -10,726,658Source | -9,750,575Source | -9,434,208Source | -7,349,056Source | -9,658,787Source | -35,665,325Source | -38,479,553Source | -44,348,217Source | -42,053,760Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | -1,169,820Source | -1,169,820Source | -869,169Source | -1,406,019Source | -1,198,905Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -9,009,411Source | -10,726,658Source | -9,750,575Source | -9,434,208Source | -7,349,056Source | -8,488,967Source | -34,495,505Source | -37,610,384Source | -42,942,198Source | -40,854,855Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.29Source | -0.18Source | -0.21Source | -0.13Source | -0.21Source | -0.74Source | -1.03Source | -1.39Source | -1.43Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.29Source | -0.18Source | -0.21Source | -0.13Source | -0.21Source | -0.74Source | -1.03Source | -1.39Source | -1.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 46,869,531Source | 36,806,592Source | 55,659,669Source | 45,902,502Source | 55,496,279Source | 40,521,001Source | 46,384,280Source | 36,452,707Source | 30,952,060Source | 28,599,221Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 46,869,531Source | 36,806,592Source | 55,659,669Source | 45,902,502Source | 55,496,279Source | 40,521,001Source | 46,384,280Source | 36,452,707Source | 30,952,060Source | 28,599,221Source |
| Interest Expense (non-operating)USD | — | — | 1,150,378Source | 1,214,734Source | 3,379,246Source | 2,144,481Source | 1,014,783Source | 930,878Source | 5,338,607Source | 4,673,174Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | -1,169,820Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 3,563,753Source | 3,374,794Source | 3,231,148Source | 3,410,433Source | 3,064,055Source | 3,274,759Source | 12,518,127Source | 13,755,671Source | 15,282,450Source | 12,241,394Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 4,205,922Source | 1,316,519Source |
| Interest Expense, DebtUSD | — | — | — | 1,211,375Source | — | — | — | — | — | 4,659,118Source | 4,187,075Source | 1,288,776Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | -869,269Source | -547,964Source | -3,253,841Source | -1,810,857Source | -827,969Source | -553,029Source | -4,121,366Source | -2,158,358Source | -1,302,983Source | -381,339Source |
| Investment Income, InterestUSD | — | — | 281,109Source | 666,770Source | 125,405Source | 333,624Source | 186,814Source | 377,849Source | 1,217,241Source | 2,514,816Source | 2,902,939Source | 935,180Source |
| Operating ExpensesUSD | — | — | 8,140,142Source | 10,178,694Source | 6,496,734Source | 7,623,351Source | 6,521,087Source | 9,105,758Source | 31,543,959Source | 36,321,195Source | 43,045,234Source | 41,672,421Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 241,029Source |
| Research and Development ExpenseUSD | — | — | 4,576,389Source | 6,803,900Source | 3,265,586Source | 4,212,918Source | 3,457,032Source | 5,830,999Source | 19,025,832Source | 22,565,524Source | 27,762,784Source | 29,431,027Source |
Offerings
Registration 333-299455
Registration 333-297386
- Offering price
- at-the-market
- Ticker
- PDSB
Registration 333-289942
Filing attachments
ef20085528_ex99-1.htm · 8-K · 2026-11-13
Exhibit 99.1 PDS Biotech Reports Third Quarter 2026 Financial Results PRINCETON, N.J., November 13, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended September 30, 2026. “During our third quarter, we continued to execute our strategic prior…
Read attachment ↗ef20085268_ex99-1.htm · 8-K · 2026-11-10
Exhibit 99.1 PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds Princeton, NJ, November 10, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced NantWorks has exercised its outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of the Company's common stock (or pre-funde…
Read attachment ↗ef20084135_ex99-1.htm · 8-K · 2026-10-21
Exhibit 99.1 Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB October 2026 Precision Designed Science for Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These state…
Read attachment ↗ef20084000_ex99-1.htm · 8-K · 2026-10-20
Exhibit 99.1 PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships PRINCETON, N.J., October 20, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-s…
Read attachment ↗ny20083600x1_ex107.htm · S-3 · 2026-10-14
Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) PDS Biotechnology Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Re…
Read attachment ↗ef20083341_ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET PRINCETON, N.J., October 6, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills can…
Read attachment ↗